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Abstract 
Primary open-angle glaucoma (POAG), the most common optic neuropathy, is a highly heritable 
disease. Intraocular pressure (IOP) and optic nerve head characteristics are used clinically to predict 
POAG risk. We conducted a genome-wide association meta-analysis of IOP and optic disc parameters 
and validated our findings in POAG cases. We identified 21 new genomic regions associated with 
optic nerve head variation and with IOP. Several genomic regions affect both IOP and the optic disc 
and we found that pathways involved in these endophenotypes are not entirely distinct as assumed. 
We further identified a novel association between CDKN1A and POAG. Using a zebrafish model we 
demonstrate that six6b (associated with POAG and optic nerve head variation) alters the expression 
of cdkn1a.  
Author Summary 
Glaucoma is a progressive eye disease that damages the optic nerve and is a leading cause of 
irreversible blindness worldwide. In this study we conducted the largest genome-wide association 
meta-analysis of the measurements used clinically to predict glaucoma risk. We identified 21 new 
genomic regions associated with these measurements and we found that CDKN1A influences 
glaucoma risk. Furthermore, we explored the interaction between CDKN1A and SIX6 (another 
glaucoma gene) in zebrafish. We identify genetic variants associated with more than one of the 
measurements analyzed, and we found new and well-known pathways. Our findings provide new 
insights into the pathways and genes that underlie glaucoma and the measurements used clinically 
to predict glaucoma risk. 
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Introduction 
In primary open-angle glaucoma (POAG), loss of retinal ganglion cells and nerve fibers manifests itself 
clinically as optic nerve damage, which leads to visual field loss and, eventually, blindness. The optic 
nerve damage is characterized by an increase in cup size, the central area of the optic nerve head (or 
optic disc). This damage can be quantified by the vertical cup-disc ratio (VCDR), comparing the 
vertical diameter of the cup with the vertical diameter of the total optic disc. 
Elevated intraocular pressure (IOP) is a well-recognized risk factor and current POAG therapies lower 
IOP by various mechanisms. Sib relative risk analyses suggest that POAG is highly heritable[1] and 
several genome-wide association studies (GWAS) have identified new POAG genes by examining 
POAG directly or studying endophenotypes like VCDR and IOP[2-11]. Several genes associated with 
VCDR and IOP - CDKN2B-AS1, SIX6 (VCDR); and CAV1/CAV2, TMCO1, ABCA1 and ARHGEF12 (IOP) - 
are highly significantly associated with POAG. Notably, no genes have been significantly (genome-
wide) associated with both VCDR and IOP. Charlesworth et al. previously found a genetic correlation 
between VCDR and IOP (RhoG = 0.45, P = 0.0012), however, genes underlying this relationship have 
not yet been identified[12]. 
The aims of this study were to (1) identify new genes associated with the POAG endophenotypes IOP, 
VCDR, cup area, and disc area, and ultimately POAG, using the 1000 Genomes imputations reference 
panel, and (2) investigate the genetic overlap between the different endophenotypes. To accomplish 
these aims we performed a meta-analysis of GWAS of these four traits within the International 
Glaucoma Genetics Consortium (IGGC). 
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Results 
Intraocular pressure 
After removal of single nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) < 0.01 
and low imputation quality, approximately 8 million SNPs were included. Whilst the analysis of 
individuals of European descent yielded no novel associations, combined analysis of individuals of 
European and Asian descent (n = 37,930, λ = 1.07; S1a, S1b and S2b Figs), yielded nine genomic 
regions reaching genome-wide significance, of which eight genomic regions were already known 
(S1a, S1b and S2b Figs, S3 Table)[4, 6, 8]. The peak SNP in the new genomic region was rs55796939 
on chromosome 11q25 near ADAMTS8 (S3 and S4 Figs). 
 
Vertical cup-disc ratio 
In the meta-analysis of individuals of European descent (n = 23,899, λ = 1.10), 21 genomic regions 
were genome-wide significant (S5a and S6a Figs, S4 Table). Five genomic regions were novel (near to 
the genes RPE65 on chr. 1p31, F5 on chr. 1q23, PDZD2 on chr. 5p13.3, RREB1 on chr. 6p25, and DGKB 
on chr. 7p21.2) (S7 and S8 Figs); the other genomic regions have been previously associated with 
VCDR or cup area, two highly correlated traits[13-15]. Of the five novel genomic regions, RREB1 (p-
value = 4.00 x 10-3) was nominally significant in the analysis of individuals of Asian descent (n= 8,373, 
λ = 1.02). In the combined analysis (n = 32,272, λ = 1.08), another four novel genomic regions, near to 
the genes VCAN on chr. 5q14.3, PSCA on chr. 8q24.2, ENO4 on chr. 10q25.3, and RBM23 on chr. 
14q11.2 (S5b and S6b Figs), were genome-wide significant leading to a total of nine (5+4) novel 
genomic regions associated with VCDR. Of these novel genomic regions, F5 has been associated with 
disc area previously[15]. Disc area influences the VCDR[16], and therefore we corrected VCDR for 
disc area in a secondary analysis. After correction for disc area, the β (p-value) decreased from -0.007 
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(2.48 x 10-9) to -0.002 (5.60 x 10-2) in the subset with disc area available, suggesting that F5 acts 
primarily on disc area and secondary to VCDR through its relation to disc area. 
 
Cup area 
The meta-analysis of individuals of European descent (n = 22,489, λ = 1.09) yielded 20 genome-wide 
significant regions of which 17 regions were already implicated for cup area or VCDR (S9a and S10a 
Figs, S5 Table)[14, 15]. There were three novel associations on chr. 1q42.11 near CDC42BPA, chr. 
8q21.11 near CRISPLD1, and on chr. 15q26.3 near FAM169B (S11 and S12 Figs). CDC42BPA has 
previously been associated with disc area and the fact that the association with cup area adjusting 
for disc area is genome wide significant suggests an independent effect on cup area. In the combined 
analysis of European and Asian individuals (n = 29,828, λ = 1.08, S9b and S10b Figs) all loci except 
FAM169B remained genome-wide significant, and there were two additional genome-wide 
significant SNPs at chr. 6p21.2 (CDKN1A) and chr. 9q34.2 (ABO; previously associated to IOP). 
 
Disc area 
The meta-analysis of individuals of European descent (n = 22,504, λ = 1.09) resulted in 13 genome-
wide significant regions, of which two were not previously associated with disc area: UGT8 on chr. 
4q26 and CTNNA3 on chr. 10q22.2 (S13a, S14a, S15, S16 Figs, and S6 Table). These SNPs were not 
significant in the meta-analysis of individuals of Asian descent (n = 7,307, λ = 1.03). An additional four 
SNPs reached genome-wide significance in the combined meta-analysis (n = 29,811, λ = 1.09): 
PRDM16 on chr. 1p36.23-p33, GADD45A on chr. 1p31.2, VGLL4 on chr. 3p25.3, and ASB7 on chr. 
15q26.3 (S13b and S14b Figs). 
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Characterization of the lead association signals 
In total, 86 SNPs were associated with one or more of the above endophenotypes. Functional 
characterization of the 86 SNPs was performed using a range of bioinformatics tools (see Methods). 
In total, 1435 variants in linkage disequilibrium (LD) with the 86 lead SNPs (R2 >0.8) were examined 
for functional annotation. Overall, 59% (51/86) of the associated loci are in LD with variants located 
in regulatory regions according to the ENCODE data (e.g. DNase I hypersensitive sites, transcription 
factor binding sites and motifs; see S7 Table). We investigated the expression levels of the identified 
candidate genes using the UniGene database[17]. Of all reviewed genes, CDKN1A, PAX6 and DUSP1 
showed the highest number of transcripts per million in the eye (S8 Table). According to the Ocular 
Tissue database[18], CDKN1A is highly expressed in the optic nerve head, as well as DUSP1, which 
also shows high expression in the trabecular meshwork. Both genes were associated with optic nerve 
head parameters. PAX6 is highly expressed in the ciliary body and retina, in this study we found it 
associated with disc area. Other highly expressed genes in the optic nerve include EFEMP1 and 
ABI3BP, which are associated with cup area and disc area, respectively (S9 Table). 
Gene-based test 
To identify new loci not found through per-SNP tests, we performed gene-based testing using 
VEGAS2. Reflecting the smaller number of tests, our gene-based significance threshold is Pgene-based < 
0.05/24,769 = 2.02 x 10-6 (24,769 genes tested). Using the gene-based test we found several novel 
loci (S10 Table). C9 was significantly associated with IOP (p-value 1.61 x 10-6); RARB (p-value 1.86 x 
10-6) and HORMAD2-AS1 (p-value 1.04 x 10-6) were associated with VCDR. These genes were 
previously associated with disc area, so the novel associations with VCDR could possibly be driven by 
the influence of disc area on VCDR[15]. In the cup area analysis, the genes LRP10 (p-value 1.20 x 10-6) 
and REM2 (p-value 1.55 x 10-6), and THSD4 (p-value 5.44 x 10 8) were significantly associated. The first 
two genes are located near to RBM23, which was significant in the per-SNP test. THSD4 is located 
near to KPNB1, which was associated with VCDR in our previous meta-analysis[14]. In the disc area 
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analysis we found two genes that were significantly associated with disc area: ANKRA2 (p-value 8.42 
x 10-7) and LOC149950 (p-value 3.87 x 10-7). 
Characterizing the overlap in biological pathways involved in glaucoma endophenotypes 
In total, 86 SNPs were associated with one or more of the above endophenotypes. The effect 
estimates and p-values of these SNPs for all four endophenotypes are shown in Table 1-3. ADAMTS8 
(IOP and VCDR, Table 1 and Table) and ABO (IOP and cup area, Table 1 and Table ) were genome-
wide significantly associated with two traits. Of note is that there were different variants involved in 
ADAMTS8: rs55796939 for IOP and rs4936099 for VCDR (r2=0.03 between these SNPs in 1000G 
European samples). Figure 1 shows the overlap in associations across endophenotypes – we depict 
annotated genes for which at least one SNP was genome-wide significant in at least one trait. 
Overlap is defined as nominal significance or stronger for the second trait. The figure shows as 
expected a strong overlap in variants associated to disc area, cup area and VCDR. Further, overlap is 
noted in genes associated to IOP, cup area and VCDR. 
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Table 1. Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with IOP and show and association with vertical cup-disc ratio.  
For these SNPs, the associations with the other traits are also included. SNPs that are Bonferroni significantly associated with other traits are shown in bold (p-value < 5.31 x 10-4; 0.05/94). In 
the first rows, the SNPs genome-wide significantly associated with intraocular pressure (IOP) are shown. Next, the SNPs associated with IOP, vertical cup-disc ratio (VCDR), and cup area are 
shown. Nearest gene, reference NCBI build37; A1, reference allele; A2, other allele; β, effect size on the endophenotype (IOP, VCDR, cup area or disc area) based on allele A1; SE, standard 
error of the effect size; i, insertion; d, deletion; r, reference.  
   IOP VCDR Cup area Disc area 
SNP Nearest gene A1/A2 β SE P β SE P β SE P Β SE P 
rs10918274 TMCO1 t/c 0.26 0.04 3.40E-12 0.005 0.002 8.60E-03 0.010 0.003 2.20E-03 -0.001 0.006 9.13E-01 
rs7635832 FNDC3B g/t -0.22 0.03 3.84E-13 -0.001 0.001 3.33E-01 -0.004 0.003 1.22E-01 0.002 0.005 7.12E-01 
rs10281637 CAV1/CAV2 c/t 0.20 0.03 2.53E-13 0.004 0.001 4.97E-03 0.006 0.003 1.13E-02 -0.003 0.005 5.81E-01 
8:78380944 PKIA i/r 1.00 0.17 6.06E-09 0.000 0.010 9.77E-01 -0.017 0.017 3.23E-01 0.018 0.031 5.50E-01 
rs7815043 PKIA c/t 0.10 0.03 3.64E-05 -0.001 0.001 3.23E-01 -0.001 0.002 8.24E-01 -0.002 0.004 5.65E-01 
rs7944735 Many genes c/g 0.20 0.03 3.97E-11 0.001 0.001 4.53E-01 0.006 0.003 2.97E-02 0.000 0.005 9.73E-01 
11:120357425 ARHGEF12 d/r 0.18 0.03 1.54E-09 0.001 0.001 5.70E-01 0.001 0.003 6.27E-01 0.001 0.005 8.20E-01 
rs12794618 ARHGEF12 c/t 0.17 0.03 6.72E-09 0.001 0.001 3.77E-01 0.002 0.003 4.62E-01 0.004 0.005 4.24E-01 
rs55796939 ADAMTS8 t/c 0.36 0.06 1.92E-08 0.003 0.003 3.77E-01 0.006 0.006 3.06E-01 -0.003 0.010 8.00E-01 
               
rs2472496 ABCA1 g/a -0.17 0.02 1.47E-13 0.005 0.001 5.69E-05 0.010 0.002 6.40E-07 0.003 0.004 4.71E-01 
rs8176741 ABO1 a/g 0.24 0.04 2.55E-10 0.007 0.002 4.06E-05 0.019 0.003 5.65E-08 0.004 0.006 5.25E-01 
rs9913911 GAS7 g/a -0.17 0.02 4.95E-12 -0.006 0.001 1.62E-07 -0.008 0.002 1.79E-04 -0.001 0.004 8.45E-01 
11 
 
Table 2a. Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with vertical cup-disc ratio and show an association with cup area and disc area 
   IOP VCDR Cup area Disc area 
SNP Nearest gene A1/A2 β SE P β SE P β SE P Β SE P 
rs6804624 COL8A1 c/t -0.01 0.02 6.63E-01 0.008 0.001 4.69E-12 0.013 0.002 1.66E-08 0.020 0.004 4.93E-07 
rs7916697 ATOH7 a/g 0.01 0.03 7.39E-01 -0.018 0.001 5.22E-46 -0.017 0.002 7.42E-13 -0.094 0.004 7.36E-110 
10:96008348 PLCE1 d/r 0.01 0.03 5.81E-01 0.007 0.001 3.50E-08 0.013 0.002 1.11E-08 0.015 0.004 1.61E-04 
rs324780 TMTC2 g/a 0.03 0.02 2.85E-01 -0.011 0.001 3.08E-23 -0.016 0.002 7.62E-14 -0.029 0.004 8.39E-14 
rs4299136 ASB7 c/g -0.03 0.03 4.13E-01 0.010 0.002 1.72E-12 0.018 0.003 3.02E-10 0.024 0.005 2.39E-06 
16:51461915 SALL1 r/i 0.02 0.03 4.23E-01 0.010 0.001 1.45E-13 0.013 0.003 5.18E-07 0.032 0.005 5.19E-13 
rs4784295 SALL1 c/g 0.02 0.03 5.61E-01 0.010 0.001 2.22E-13 0.013 0.002 1.19E-07 0.031 0.004 1.99E-12 
rs5752773 CHEK2 g/c 0.01 0.03 6.89E-01 -0.012 0.001 7.90E-21 -0.024 0.003 1.25E-21 -0.024 0.004 5.28E-08 
rs2092172 CARD10 a/g 0.00 0.03 8.88E-01 0.009 0.001 1.92E-12 0.011 0.003 2.91E-05 0.032 0.005 3.84E-12 
rs7717697 VCAN c/t 0.01 0.02 7.27E-01 -0.007 0.001 4.39E-09 -0.009 0.002 1.12E-05 -0.018 0.004 2.16E-06 
rs1681739 ENO4 t/c 0.03 0.02 2.19E-01 0.006 0.001 2.12E-08 0.011 0.002 3.32E-07 0.019 0.004 1.04E-06 
rs60779155 ASB7 a/g -0.02 0.03 6.57E-01 0.010 0.002 2.67E-10 0.019 0.003 2.92E-09 0.030 0.005 3.28E-08 
rs1830890 PLCE1 g/a 0.01 0.02 8.27E-01 0.006 0.001 2.49E-08 0.012 0.002 6.52E-08 0.014 0.004 3.60E-04 
rs482507 TMTC2 c/t 0.02 0.02 3.52E-01 -0.011 0.001 1.03E-19 -0.017 0.002 1.15E-14 -0.030 0.004 5.03E-14 
rs4436712 SIX6 t/g -0.04 0.02 1.40E-01 0.009 0.001 3.58E-14 0.025 0.002 1.88E-30 -0.018 0.004 3.71E-06 
rs738722 CHEK2 t/c 0.02 0.03 3.61E-01 -0.012 0.001 2.78E-20 -0.024 0.003 2.35E-22 -0.021 0.004 1.59E-06 
rs2684249 HSF2 c/t 0.03 0.02 2.10E-01 -0.006 0.001 1.47E-07 -0.012 0.002 1.96E-08 -0.015 0.004 9.56E-05 
rs34222435 ASB7 t/c -0.03 0.03 3.77E-01 0.010 0.002 1.95E-12 0.019 0.003 7.65E-11 0.025 0.005 1.29E-06 
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   IOP VCDR Cup area Disc area 
SNP Nearest gene A1/A2 β SE P β SE P β SE P Β SE P 
rs7916410 ATOH7 t/c 0.00 0.03 9.76E-01 -0.018 0.001 2.23E-46 -0.017 0.002 3.57E-12 -0.097 0.004 1.97E-114 
rs442376 TMTC2 c/t -0.03 0.03 3.15E-01 0.011 0.001 6.80E-18 0.017 0.002 1.59E-12 0.032 0.004 9.79E-15 
rs1345467 SALL1 g/a 0.01 0.03 6.55E-01 0.009 0.001 2.91E-12 0.012 0.003 8.53E-07 0.032 0.004 1.19E-13 
rs5762752 CHEK2 c/g 0.01 0.03 6.58E-01 -0.011 0.001 2.29E-18 -0.021 0.002 2.58E-19 -0.023 0.004 1.17E-08 
rs11129176 RARB a/g 0.02 0.03 4.11E-01 0.005 0.001 3.14E-05 0.010 0.002 8.59E-06 0.023 0.004 1.02E-08 
rs1997404 COL8A1 g/t -0.02 0.03 3.28E-01 0.008 0.001 1.36E-11 0.013 0.002 6.58E-08 0.024 0.004 7.31E-09 
rs34935520 SIX6 g/a -0.04 0.02 1.09E-01 0.009 0.001 5.41E-14 0.025 0.002 9.85E-30 -0.022 0.004 2.39E-08 
For these SNPs, the associations with the other traits are also included. Here the SNPs genome-wide significantly associated with vertical cup-disc ratio that are Bonferroni significantly 
associated with cup area or disc area are shown in bold (p-value < 5.31 x 10-4; 0.05/94).Nearest gene, reference NCBI build37; A1, reference allele; A2, other allele; β, effect size on the effect 
size on the endophenotype (IOP, VCDR, cup area or disc area) based on allele A1; SE, standard error of the effect size; i, insertion; d, deletion; r, reference. 
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Table2b. Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with vertical cup-disc ratio and show an association with cup area  
   IOP VCDR Cup area Disc area 
SNP Nearest gene A1/A2 β SE P β SE P β SE P Β SE P 
rs1925953 RPE65 t/a -0.02 0.02 3.13E-01 0.006 0.001 1.10E-07 0.010 0.002 1.20E-05 0.006 0.004 9.98E-02 
rs72759609 PDZD2 c/t -0.04 0.05 3.38E-01 -0.012 0.002 5.21E-09 -0.020 0.004 1.23E-06 -0.021 0.008 4.69E-03 
rs114503346 DUSP1 t/c -0.12 0.08 1.19E-01 -0.021 0.004 1.02E-08 -0.036 0.007 1.49E-07 -0.035 0.012 4.84E-03 
rs4960295 RREB1 a/g 0.02 0.02 4.65E-01 0.007 0.001 1.93E-10 0.009 0.002 2.52E-05 0.012 0.004 2.26E-03 
rs10274998 DGKB t/c 0.02 0.03 4.31E-01 0.008 0.001 3.91E-08 0.012 0.003 5.87E-06 0.011 0.005 2.09E-02 
rs2157719 CDKN2B-AS1 c/t -0.04 0.02 9.20E-02 -0.013 0.001 1.30E-35 -0.024 0.002 5.41E-29 -0.008 0.004 2.61E-02 
rs3891783 PLCE1 g/c 0.04 0.02 1.01E-01 0.007 0.001 8.01E-11 0.011 0.002 2.09E-07 0.012 0.004 8.58E-04 
rs1346 SSSCA1 t/a -0.05 0.03 1.11E-01 -0.013 0.001 3.88E-18 -0.019 0.003 5.20E-11 -0.016 0.005 1.59E-03 
rs4936099 ADAMTS8 c/a -0.03 0.03 2.31E-01 -0.007 0.001 5.16E-09 -0.013 0.002 3.34E-08 -0.006 0.004 1.50E-01 
13:36629905 DCLK1 d/r -0.02 0.03 5.76E-01 0.007 0.001 2.45E-08 0.018 0.002 1.12E-14 -0.005 0.004 2.26E-01 
rs7323428 DCLK1 t/g -0.02 0.03 4.12E-01 0.007 0.001 1.56E-08 0.019 0.002 8.63E-16 -0.005 0.004 2.08E-01 
rs8015152 SIX6 t/c -0.06 0.02 2.03E-02 0.010 0.001 1.34E-18 0.024 0.002 2.01E-26 -0.011 0.004 5.18E-03 
rs6107845 BMP2 a/g 0.03 0.02 2.89E-01 -0.009 0.001 2.12E-17 -0.017 0.002 1.45E-15 -0.004 0.004 3.22E-01 
rs6764184 FLNB t/g 0.05 0.03 5.25E-02 0.007 0.001 1.50E-08 0.015 0.002 1.01E-10 0.010 0.004 1.51E-02 
rs7311936 FAM101A c/g -0.03 0.02 1.56E-01 -0.006 0.001 1.87E-09 -0.013 0.002 2.35E-09 0.003 0.004 5.21E-01 
14:23388793 RBM23 r/d 0.02 0.03 4.00E-01 0.007 0.001 2.13E-08 0.013 0.003 1.47E-07 0.009 0.004 3.48E-02 
rs3794453 RBM23 a/t 0.01 0.02 7.29E-01 0.007 0.001 5.85E-08 0.011 0.002 2.10E-07 0.009 0.004 2.65E-02 
rs2252865 RERE t/c 0.05 0.02 3.75E-02 0.005 0.001 1.95E-05 0.014 0.002 6.69E-10 0.003 0.004 5.13E-01 
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   IOP VCDR Cup area Disc area 
SNP Nearest gene A1/A2 β SE P β SE P β SE P Β SE P 
rs4846112 DHRS3 a/g -0.02 0.03 5.23E-01 -0.005 0.001 2.22E-04 -0.012 0.002 1.67E-07 0.005 0.004 2.21E-01 
rs13016883 TRIB2 c/g 0.02 0.03 5.48E-01 0.006 0.001 2.53E-06 0.016 0.002 1.05E-11 0.001 0.004 8.23E-01 
rs35084382 DUSP1 c/t -0.10 0.07 1.25E-01 -0.018 0.003 1.56E-08 -0.034 0.006 1.16E-08 -0.030 0.011 4.57E-03 
rs117598310 CRISPLD1 t/g -0.05 0.05 3.09E-01 0.009 0.002 1.00E-04 0.021 0.004 1.32E-06 0.022 0.008 4.96E-03 
rs1360589 CDKN2B-AS1 c/t -0.04 0.02 7.91E-02 -0.013 0.001 5.05E-35 -0.024 0.002 4.51E-29 -0.008 0.004 3.65E-02 
rs11613189 FAM101A t/c -0.03 0.03 2.08E-01 -0.005 0.001 4.79E-06 -0.016 0.002 8.66E-13 0.002 0.004 6.49E-01 
rs2251069 DDHD1 c/t 0.01 0.02 7.33E-01 -0.006 0.001 7.12E-08 -0.013 0.002 5.69E-10 0.001 0.004 7.33E-01 
rs6598351 FAM169B t/c -0.02 0.03 5.30E-01 0.006 0.001 2.34E-05 0.012 0.003 1.19E-05 -0.004 0.005 3.83E-01 
rs11646917 SALL1 t/g -0.01 0.03 6.71E-01 -0.009 0.001 3.43E-10 -0.015 0.003 2.54E-09 -0.015 0.005 1.16E-03 
rs11867840 BCAS3 g/a 0.04 0.03 1.04E-01 -0.006 0.001 3.89E-06 -0.018 0.002 1.15E-13 0.012 0.004 7.36E-03 
rs6054375 BMP2 t/g 0.03 0.03 2.57E-01 -0.010 0.001 4.10E-15 -0.018 0.002 8.77E-16 -0.003 0.004 4.72E-01 
rs3791679 EFEMP1/PNPT1 g/a 0.04 0.03 1.66E-01 -0.005 0.001 1.02E-04 -0.013 0.002 2.94E-08 0.003 0.004 4.93E-01 
rs12494328 FLNB a/g 0.04 0.03 1.56E-01 0.006 0.001 1.43E-06 0.016 0.002 4.39E-11 0.009 0.004 3.96E-02 
6:36592986 CDKN1A d/r -0.02 0.03 5.08E-01 0.006 0.001 1.60E-05 0.015 0.003 7.85E-09 -0.006 0.005 2.04E-01 
rs72852338 CDKN1A c/a -0.02 0.03 5.19E-01 0.006 0.001 2.74E-05 0.014 0.003 2.26E-08 -0.005 0.005 2.96E-01 
rs1074407 TRIOBP t/a 0.11 0.02 3.42E-06 0.006 0.001 2.66E-07 0.012 0.002 1.17E-08 0.008 0.004 3.15E-02 
For these SNPs, the associations with the other traits are also included. Here the SNPs genome-wide significantly associated with vertical cup-disc ratio that are Bonferroni significantly 
associated with cup area are shown in bold (p-value < 5.31 x 10-4; 0.05/94).Nearest gene, reference NCBI build37; A1, reference allele; A2, other allele; β, effect size on effect size on the 
endophenotype (IOP, VCDR, cup area or disc area) based on allele A1; SE, standard error of the effect size; i, insertion; d, deletion; r, reference. 
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Table2c. Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with vertical cup-disc ratio and show an association with disc area 
   IOP VCDR Cup area Disc area 
SNP Nearest gene A1/A2 β SE P β SE P β SE P Β SE P 
rs1192414 CDC7/TGFBR3 a/g 0.06 0.03 5.39E-02 0.014 0.001 8.18E-24 0.007 0.003 1.07E-02 0.087 0.005 3.78E-74 
rs10753787 F5 t/c -0.03 0.02 1.80E-01 -0.007 0.001 2.11E-09 -0.005 0.002 1.84E-02 -0.019 0.004 9.12E-07 
rs2920293 PSCA g/c 0.00 0.02 8.67E-01 -0.006 0.001 4.95E-09 -0.007 0.002 7.60E-04 -0.015 0.004 5.41E-05 
rs4658101 CDC7/TGFBR3 a/g 0.06 0.03 4.24E-02 0.013 0.001 2.35E-23 0.007 0.003 1.09E-02 0.089 0.005 2.35E-82 
1:169530520 F5/SELP i/r 0.02 0.03 4.44E-01 0.007 0.001 6.29E-07 0.005 0.003 5.33E-02 0.032 0.005 5.13E-13 
rs2239854 F5/SELP a/g 0.03 0.03 2.73E-01 0.006 0.001 6.94E-07 0.005 0.002 4.94E-02 0.030 0.004 3.43E-13 
rs9843102 ABI3BP a/g 0.00 0.03 9.91E-01 -0.006 0.002 2.01E-04 -0.002 0.003 5.89E-01 -0.036 0.005 3.99E-12 
8:88744441 DCAF4L2 d/r -0.01 0.02 6.98E-01 0.006 0.001 4.50E-07 0.006 0.002 4.47E-03 0.026 0.004 7.15E-12 
rs6468996 DCAF4L2 t/c 0.00 0.02 9.19E-01 0.005 0.001 1.86E-07 0.006 0.002 2.11E-03 0.025 0.004 8.07E-12 
rs61101201 ELP4/PAX6 g/t 0.02 0.03 5.33E-01 0.006 0.001 1.85E-06 0.005 0.002 3.91E-02 0.028 0.004 3.52E-11 
rs56385951 CARD10 a/g -0.06 0.04 8.65E-02 0.011 0.002 1.36E-11 0.008 0.003 8.50E-03 0.047 0.006 2.48E-17 
1:3046430 PRDM16 i/r -0.04 0.04 4.19E-01 0.007 0.002 5.00E-04 -0.001 0.004 7.18E-01 0.044 0.007 5.15E-10 
rs12028027 PRDM16 c/t -0.03 0.04 5.03E-01 0.007 0.002 2.02E-04 -0.001 0.004 8.62E-01 0.043 0.007 6.02E-10 
For these SNPs, the associations with the other traits are also included. Here the SNPs genome-wide significantly associated with vertical cup-disc ratio that are Bonferroni significantly 
associated with disc area are shown in bold (p-value < 5.31 x 10-4; 0.05/94).Nearest gene, reference NCBI build37; β, effect size on effect size on the endophenotype (IOP, VCDR, cup area or 
disc area) based on allele A1; SE, standard error of the effect size; i, insertion; d, deletion; r, reference. 
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Table 3 Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with optic nerve head parameters (cup area and disc area) 
   IOP VCDR Cup area Disc area 
SNP Nearest gene A1/A2 β SE P β SE P β SE P Β SE P 
1:227562773 CDC42BPA d/r -0.10 0.05 2.74E-02 0.003 0.002 2.39E-01 0.024 0.004 4.60E-09 -0.055 0.007 4.93E-14 
rs73102394 CDC42BPA t/c -0.09 0.04 3.92E-02 0.003 0.002 1.60E-01 0.022 0.004 2.53E-08 -0.053 0.007 6.79E-14 
rs11811982 CDC42BPA a/c -0.12 0.05 1.21E-02 0.004 0.002 5.48E-02 0.027 0.004 1.32E-10 -0.062 0.008 1.74E-16 
               
rs10021731 UGT8 c/t 0.01 0.02 8.26E-01 -0.002 0.001 5.60E-02 -0.002 0.002 2.63E-01 -0.020 0.004 2.44E-07 
rs12220165 CTNNA3 g/c 0.02 0.03 5.94E-01 -0.004 0.002 1.41E-02 -0.004 0.003 1.76E-01 -0.023 0.005 1.75E-05 
rs787541 U6, GADD45A c/g 0.07 0.03 7.17E-03 0.002 0.001 7.26E-02 0.002 0.002 5.06E-01 0.023 0.004 3.16E-08 
rs1367187 DIRC3 c/t -0.07 0.03 9.01E-03 0.002 0.001 2.63E-01 -0.002 0.003 4.79E-01 0.026 0.005 5.96E-09 
rs2443724 VGLL4 c/g 0.00 0.02 8.77E-01 -0.003 0.001 1.50E-02 0.000 0.002 9.47E-01 -0.022 0.004 1.40E-08 
rs1013830 CTNNA3 t/c 0.00 0.05 9.53E-01 -0.007 0.002 4.70E-03 -0.004 0.005 3.96E-01 -0.045 0.008 2.00E-08 
 
For these SNPs, the associations with the other traits are also included. SNPs that are Bonferroni significantly associated with other traits are shown in bold (p-value < 5.31 x 10-4; 0.05/94). In 
the first rows, the SNPs genome-wide significantly associated with cup area are shown. Next, SNPs associated with only disc area, are shown. Nearest gene, reference NCBI build37; A1, 
reference allele; A2, other allele; β, effect size on the endophenotype (IOP, VCDR, cup area or disc area) based on allele A1; SE, standard error of the effect size; i, insertion; d, deletion; r, 
reference. 
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Figure 1. Overlap between the genes associated with one or more endophenotypes. Genes with genome-wide significant association for at least one trait 
are shown. These genes are counted as overlapping genes if they are Bonferroni significantly associated with the other trait(s). Chr 11p11.2 (see intraocular 
pressure circle) means a region on chromosome 11p11.2 that is associated with IOP and has many genes in it; the likely causative gene in this region is not 
identified yet. Genes in bold are genes associated with primary open-angle glaucoma (POAG) in our meta-analysis of four case-control studies.*Genes 
associated with familial forms of POAG (e.g. MYOC and OPTN) or found in case-control association studies which did not show an association with the 
endophenotypes explored in this study. 
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To further characterize the overlap in biological functions, gene set enrichment of loci associated 
with IOP and optic disc parameters was performed using DEPICT[19]. We first investigated enriched 
pathways or gene sets using only genome-wide associated SNPs. No significant pathways were found 
after FDR correction. However, pathways involved in metabolic processes such as “increased 
circulating leptin level”, “abnormal fat cell morphology” and “increased insulin sensitivity” were 
suggestive when we analyzed the list of SNPs associated with VCDR, cup area and disc area (FDR<0.2, 
see S11 Table). We next searched for enriched pathways using suggestive SNPs (p-value <1.0 x 10-5). 
We further investigated potential overlap in pathways across the endophenotypes, and found 57 
significant pathways when using VCDR, cup area and IOP variants; and 100 pathways when analysing 
suggestive VCDR, cup area and disc area variants. Note that in the first analysis we investigated 
pathways enriched when IOP genes are taken into account, while in the second one we analysed 
genes influencing the optic nerve head characteristics. Due to a high degree of redundancy between 
pathways, we clustered the significant pathways into meta-pathways, resulting in 11 meta-pathways 
for VCDR, cup area and IOP (Figure 2a, S12 Table); and 17 for VCDR, cup area, and disc area (Figure 
2b, S13 Table). Most of the gene sets found in both analyses highlighted pathways involved in cell 
differentiation, notch signaling, regulatory DNA binding and embryonic development, which reflects 
the pathways found when VCDR and CA variants are analyzed (S17 Fig). Furthermore, we found 
“abnormal fat cell morphology” and “abnormal liver morphology” significantly enriched; a key gene 
in these pathways is ABCA1. When IOP genes are included the elongation factor, RNA Polymerase II 
(ELL2) protein complex” shows an enrichment. When disc area genes are included, pathways such as 
“blood vessel development”, “protein import into nucleus”, “Thrombospondin 1 (THBS1) and SMAD3 
protein complex”, and “abnormal eye morphology” were significant. Key genes in the latter include: 
CDKN2B, FAT4, LRIG3, SIX6, COL8A1, SOX11, RND3, BOC, WNT2B and CYP26A1. 
Figure 2. Pathways significantly enriched for: A) Loci associated with vertical cup-disc ratio, cup area 
and intraocular pressure (p-value <7.0 x 10-6 in the GWAS). In total 11 meta-pathways were identified 
after clustering the 57 pathways identified by DEPICT. B) Loci associated with vertical cup-disc ratio, 
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cup area and disc area (p-value <1.0 x 10-5). In total 17 meta-pathways were identified after 
clustering the 100 pathways identified by DEPICT. In both figures meta-pathways are represented by 
nodes coloured according to statistical significance, and edges are scaled according to the correlation 
between meta-pathways. *The pathway “Abnormal eye morphology” clustered with the meta-
pathway “Chordate embryonic development”. ELL2=Elongation Factor, RNA Polymerase II, , DVL3= 
Dishevelled Segment Polarity Protein 3, THBS1=Thrombospondin 1, RFX2= Regulatory Factor X, 2. 
MDFI=MyoD Family Inhibitor.  
 
From endophenotypes to primary open-angle glaucoma 
Of the 75 independent (i.e. R2 < 0.8) SNPs that were associated with one or more of the 
endophenotypes, 32 were nominal significantly associated with POAG in a meta-analysis of 6,429 
cases and 41,404 controls (p-value <0.05; the chance that 32 SNPs of 75 SNPs have a p-value <0.05 is 
< 2.2 x 10-16), and 11 independent SNPs were Bonferroni significantly associated with POAG (p-value 
0.05/75 = 6.67 x 10-4) (Table 4). Of these, the rs2487048 in the ABCA1 gene and the 11:120357425 in 
the ARHGEF12 showed high heterogeneity (I2). To estimate the common effect size we performed a 
random effect meta-analysis. The odds ratio (OR) remained almost the same for both variants, 
although p-values were not significant after adjusting for multiple testing, which is in line with the 
heterogeneity observed. All other nine SNPs surpassed the Bonferroni threshold for significance in 
both fixed and random-effect models. The association between CDKN1A and POAG is novel (OR = 
1.14, p-value = 7.4 x 10-7). In our previous paper, the SNP rs6054374 near to BMP2 was already 
associated with POAG (OR = 0.92, p-value 3.74 x 10-3), but the most significantly associated SNP in 
the current meta-analysis rs6107845 near to BMP2 shows a slightly larger effect on POAG (OR = 0.89, 
p-value = 8.52 x 10-6). CDKN1A is a novel gene in the same gene family as CDKN2B, a gene previously 
associated to glaucoma. Both CDKN1A and CDKN2B are cell-cycle genes. 
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Table 4. Association with primary open-angle glaucoma in a meta-analysis of four independent 
glaucoma case-control studies (ANZRAG, NEIGHBORHOOD, Singapore, and Southampton).  
 Nearest gene A1/A2 OR OR 
(R) 
95% CI P-value P-value 
(R) 
Direction I2 P-value of 
heterogeneity 
IOP SNPs 
rs10918274 TMCO1 t/c 1.39 1.39 1.3-1.5 2.75E-19 1.37E-09 ++++ 38.4 1.82E-01 
rs7635832 FNDC3B g/t 0.89 0.91 0.83-0.95 1.41E-03 3.65E-02 ---? 33.9 2.20E-01 
rs10281637 CAV1/CAV2 c/t 1.13 1.13 1.07-1.20 2.32E-05 2.32E-05 ++++ 0 4.89E-01 
rs2487048 ABCA1 a/g 1.26 1.26 1.19-1.33 2.65E-15 3.82E-03 ++++ 82.9 5.53E-04 
rs8176741 ABO1 a/g 1.07 1.04 0.99-1.17 7.36E-02 5.25E-01 -+-+ 58.5 6.51E-02 
rs7944735 Many genes 
(NUP160, PTPRJ) 
c/g 1.06 1.07 1.01-1.13 2.99E-02 2.99E-02 ++++ 0 8.99E-01 
11:120357425 ARHGEF12 d/r 1.16 1.19 1.09-1.23 1.52E-06 3.02E-02 ++++ 83.2 4.65E-04 
rs55796939 ADAMTS8 t/c 1.07 1.17 0.94-1.24 2.72E-01 4.46E-01 +?-- 78.6 9.35E-03 
rs9913911 GAS7 g/a 0.80 0.80 0.76-0.84 1.08E-17 1.08E-17 ---- 0 7.50E-01 
 VCDR SNPs 
rs1925953 RPE65 t/a  1.07 1.10 1.02-1.13 4.21E-03 2.01E-02 ++++ 46.7 1.31E-01 
rs1192414 CDC7/TGFBR3 a/g 1.08 1.08 1.02-1.16 9.26E-03 9.26E-03 ++++ 0 7.27E-01 
rs10753787 F5 t/c 0.97 0.97 0.93-1.03 3.67E-01 3.67E-01 ---- 0 9.92E-01 
rs6804624 COL8A1 c/t 0.99 0.99 0.94-1.05 8.14E-01 8.14E-01 ---+ 0 8.42E-01 
rs72759609 PDZD2 c/t 0.90 0.91 0.83-0.99 3.20E-02 3.20E-02 ---- 0 9.53E-01 
rs114503346 DUSP1 t/c 1.00 1.00 0.80-1.25 9.99E-01 8.80E-01 +?-+ 42 1.78E-01 
rs4960295 RREB1 a/g 0.99 1.00 0.95-1.05 9.50E-01 9.09E-01 -+-+ 4.6 3.70E-01 
rs10274998 DGKB t/c 1.03 1.04 0.98-1.10 2.16E-01 2.16E-01 ++-+ 0 5.38E-01 
rs2157719 CDKN2B-AS1 c/t 0.69 0.69 0.66-0.74 1.29E-40 1.29E-40 ---- 0 5.67E-01 
rs1900005 ATOH7 a/c 1.01 1.01 0.96-1.07 6.98E-01 6.77E-01 +-++ 5.1 3.67E-01 
10:96008348 PLCE1 d/r 1.02 1.04 0.97-1.09 3.38E-01 3.15E-01 +-+? 35.3 2.13E-01 
rs1346 SSSCA1 t/a 0.90 0.91 0.85-0.97 2.41E-03 2.41E-03 ---- 0 9.04E-01 
rs4936099 ADAMTS8 c/a 0.94 0.94 0.9-1.00 5.75E-02 5.75E-02 ---- 0 9.63E-01 
rs324780 TMTC2 g/a 0.93 0.93 0.89-0.99 1.35E-02 1.35E-02 ---- 0 7.69E-01 
13:36629905 DCLK1 d/r 0.99 0.99 0.94-1.05 7.53E-01 8.00E-01 --+- 6.2 3.62E-01 
rs8015152 SIX6 t/c 1.21 1.19 1.16-1.28 3.90E-15 7.08E-05 ++++ 62.4 4.62E-02 
rs4299136 ASB7 c/g 1.03 1.03 0.97-1.10 3.55E-01 3.55E-01 ++-+ 0 8.29E-01 
16:51461915 SALL1 i/r 0.94 0.94 0.89-1 3.85E-02 3.85E-02 ---- 0 7.82E-01 
rs6107845 BMP2 a/g 0.89 0.91 0.85-0.94 1.02E-05 6.94E-03 ---- 43.1 1.53E-01 
rs5752773 CHEK2 g/c 0.92 0.92 0.88-0.98 4.63E-03 4.63E-03 ---- 0 9.12E-01 
rs2092172 CARD10 a/g 0.97 0.98 0.92-1.04 4.35E-01 4.35E-01 --+- 0 7.76E-01 
rs6764184 FLNB t/g 1.07 1.02 1.02-1.13 5.73E-03 7.66E-01 ++-+ 86.1 8.14E-05 
rs7717697 VCAN c/t 0.98 0.98 0.93-1.04 5.26E-01 5.26E-01 ---? 0 7.30E-01 
rs2920293 PSCA g/c 1.03 1.03 0.98-1.09 2.25E-01 2.25E-01  ++-? 0 3.79E-01 
rs1681739 ENO4 t/c 1.02 1.03 0.97-1.08 3.92E-01 3.99E-01 +--+ 49.2 1.16E-01 
rs7311936 FAM101A c/g 0.99 1.00 0.95-1.04 8.12E-01 8.59E-01 +--- 11 3.38E-01 
14:23388793 RBM23 r/d 1.03 1.03 0.98-1.1 1.83E-01 1.83E-01 +++? 0 4.61E-01 
 
Cup area  SNPs 
rs2252865 RERE t/c 1.11 1.11 1.06-1.18 5.76E-05 2.87E-02 ++-+ 59.3 6.10E-02 
rs4846112 DHRS3 a/g 0.95 0.96 0.91-1.01 1.18E-01 1.18E-01 ---- 0 5.53E-01 
1:227562773 CDC42BPA d/r 0.87 0.90 0.79-0.97 1.14E-02 2.11E-01 --+? 48.6 1.43E-01 
rs13016883 TRIB2 c/g 1.08 1.08 1.03-1.14 4.25E-03 4.25E-03 +++? 0 8.63E-01 
rs35084382 DUSP1 c/t 1.04 1.05 0.85-1.29 6.72E-01 6.72E-01  +?-+ 0 3.91E-01 
rs117598310 CRISPLD1 t/g 1.08 1.09 1-1.19 5.39E-02 5.39E-02 +++ 0 8.01E-01 
rs1360589 CDKN2B-AS1 c/t 0.69 0.69 0.66-0.73 1.90E-42 1.90E-42 ---- 0 6.47E-01 
rs10998036 ATOH7 c/g 1.01 1.02 0.96-1.08 5.42E-01 5.72E-01 +--- 26 2.55E-01 
10:96008348 PLCE1 d/r 1.02 1.04 0.97-1.09 3.38E-01 3.15E-01 +-+? 35.3 2.13E-01 
rs1346 SSSCA1 t/a  0.90 0.91 0.85-0.97 2.41E-03 2.41E-03 ---- 0 9.04E-01 
rs482507 TMTC2 c/t 0.94 0.94 0.89-0.99 2.03E-02 2.03E-02 ---- 0 7.46E-01 
rs11613189 FAM101A t/c 0.99 0.99 0.95-1.05 8.25E-01 7.77E-01 ++-- 18.5 2.98E-01 
rs7323428 DCLK1 t/g 0.99 1.00 0.94-1.05 7.83E-01 8.87E-01 +-+- 13.6 3.25E-01 
rs2251069 DDHD1 c/t 0.95 0.96 0.91-1.00 7.62E-02 7.62E-02  --+- 0 4.08E-01 
rs4436712 SIX6 t/g 1.24 1.23 
 
 
 
1.19-1.31 5.77E-18 1.52E-07 ++++ 48.8 1.19E-01 
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 Nearest gene A1/A2 OR OR 
(R) 
95% CI P-value P-value 
(R) 
Direction I2 P-value of 
heterogeneity 
Cup area  SNPs 
rs6598351 FAM169B t/c 0.99 0.99 0.93-1.06 8.06E-01 8.06E-01 -+-- 0 7.11E-01 
rs11646917 SALL1 t/3g 0.98 0.98 0.93-1.04 5.49E-01 5.49E-01 --++ 0 5.97E-01 
rs11867840 BCAS3 g/a 1.06 1.06 1.01-1.13 1.83E-02 2.12E-02 ++++ 8.3 3.51E-01 
rs6054375 BMP2 t/g 0.89 0.91 0.85-0.94 8.52E-06 9.93E-03 ---- 47.1 1.29E-01 
rs738722 CHEK2 t/c 0.93 0.93 0.89-0.99 1.26E-02 1.26E-02 ---- 0 9.05E-01 
rs3791679 EFEMP1/PNPT1 a/g 0.96 0.96 0.92-1.02 2.23E-01 2.23E-01 ---- 0 5.51E-01 
rs12494328 FLNB a/g 1.13 1.13 1.07-1.2 1.28E-05 5.89E-04 ++-+ 26.9 2.50E-01 
rs6804624 COL8A1 c/t 0.99 0.99 0.94-1.05 8.14E-01 8.14E-01 ---+ 0 8.42E-01 
6:36592986 CDKN1A d/r 1.14 1.15 1.09-1.21 7.74E-07 1.04E-04 ++++ 36.6 1.93E-01 
rs2684249 HSF2 c/t 0.92 0.94 0.88-0.97 1.08E-03 1.66E-01 ---+ 63.3 4.25E-02 
rs8176672 ABO t/c 1.00 1.00 91-1.11 9.49E-01 9.49E-01 -+-? 0 3.69E-01 
rs4936099 ADAMTS8 c/a 0.94 0.94 0.9-1.00 5.75E-02 5.75E-02 ---- 0 9.63E-01 
rs34222435 ASB7 t/c 1.03 1.03 0.97-1.10 3.66E-01 3.66E-01 ++-+ 0 8.74E-01 
rs1074407 TRIOBP t/a 1.04 1.04 1.00-1.10 4.92E-02 8.66E-02 ++++ 32.9 2.15E-01 
  Disc Area SNPs 
rs4658101 CDC7/TGFBR3 a/g 1.08 1.08 1.02-1.16 7.81E-03 7.81E-03 ++++ 0 7.22E-01 
1:169530520 F5/SELP i/r 1.01 1.02 0.96-1.08 5.40E-01 5.40E-01 ++-? 0 7.14E-01 
rs11811982 CDC42BPA a/c 0.87 0.90 0.8-0.97 1.19E-02 8.28E-02 --++ 20.5 2.87E-01 
rs9843102 ABI3BP a/g 0.92 0.92 0.86-0.98 1.37E-02 1.37E-02 ---- 0 6.24E-01 
rs10021731 UGT8 c/t 1.01 1.01 0.96-1.06 6.82E-01 6.82E-01  --++ 0 6.50E-01 
8:88744441 DCAF4L2 d/r 1.03 1.04 0.99-1.09 0.1225 1.39E-01 ++-+ 4.9 3.68E-01 
rs12220165 CTNNA3 g/c 1.08 1.09 1.01-1.16 1.14E-02 1.14E-02 ++++ 0 9.04E-01 
rs7916410 ATOH7 t/c 1.00 1.00 0.96-1.06 7.63E-01 7.45E-01 +-++ 3.9 3.73E-01 
rs61101201 ELP4/PAX6 g/t 1.00 1.00 0.94-1.06 9.77E-01 9.77E-01  -+-? 0 9.63E-01 
rs442376 TMTC2 c/t 1.04 1.05 0.99-1.10 7.94E-02 7.94E-02  -+++ 0 6.82E-01 
rs1345467 SALL1 g/a  1.07 1.07 1.01-1.14 1.86E-02 1.86E-02 ++++ 0 8.73E-01 
rs5762752 CHEK2 c/g 0.92 0.92 0.88-0.98 4.90E-03 4.90E-03 ---- 0 8.29E-01 
rs56385951 CARD10 a/g 0.99 1.00 0.92-1.07 9.15E-01 9.15E-01 +-+- 0 9.88E-01 
1:3046430 PRDM16 i/r 0.97 0.98 0.87-1.10 7.13E-01 8.72E-01 +--? 63.9 6.28E-02 
rs787541 U6, GADD45A c/g 0.98 0.98 0.94-1.04 6.10E-01 9.06E-01 --++ 50.7 1.08E-01 
rs1367187 DIRC3 c/t 0.95 0.96 0.9-1.01 1.11E-01 4.12E-01  +-+- 46.1 1.35E-01 
rs2443724 VGLL4 c/g 0.91 0.91 0.87-0.97 1.04E-03 2.61E-02 --+- 38 1.84E-01 
rs11129176 RARB a/g 0.99 1.00 0.94-1.05 8.85E-01 9.93E-01 +--- 40.4 1.69E-01 
rs1997404 COL8A1 g/t 1.00 1.00 0.95-1.06 9.60E-01 9.60E-01  -+++ 0 6.18E-01 
rs34935520 SIX6 g/a 1.26 1.26 1.20-1.33 2.82E-20 6.73E-14 ++++ 21.5 2.81E-01 
rs60779155 ASB7 a/g 1.02 1.03 0.96-1.10 4.52E-01 4.52E-01 +--+ 0 5.02E-01 
Results are shown for the most significantly associated single nucleotide polymorphisms from the endophenotype analyses. 
Nearest gene, reference NCBI build37; A1, reference allele; A2, other allele; OR, estimated odds ratio for allele A1; OR (R), 
estimated odds ratio for allele A1 in random effect meta-analysis; 95% CI, confidence interval; P-value (R), p-value in 
random effect meta-analysis; I2 statistic measuring heterogeneity on a scale of 0% to 100%; i, insertion; d, deletion; r, 
reference. 
 
Expression of cdkn1a after knockdown of six6b in zebrafish 
In a previous zebrafish model[20], we demonstrated that downregulation of the POAG gene six6b 
leads to up-regulation of CDKN2B, another well-known POAG gene. This zebrafish model, rather than  
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a POAG model, allowed us to investigate the downstream effects of six6b depletion, and possible 
mechanisms underlying POAG. In this study, we tested whether knockdown of six6b also alters the 
expression of the newly identified cdkn1a gene in vivo. Knockdown of six6b was achieved using 
morpholino technology[20]. 85% of the knockdown embryos showed a small eye phenotype, 
reduced optic nerve thickness and an up-regulation of the expression levels of cdkn2a/cdkn2b, as 
observed in previous studies (n=220)[20, 21]. In zebrafish, there is only one gene which is analogous 
to the human CDKN2A and CDKN2B and it is referred to in this paper as cdkn2a/cdkn2b. Both 
SIX6and CDKN2B are part of the abnormal eye morphology pathway found with DEPICT, which is in 
line with previous findings. In silico analyses showed that SIX6 binds to both CDKN2B (core score = 1) 
and CDKN1A (core score = 0.812). . We evaluated the expression levels of cdkn1a in six6b deficient 
embryos by RT-qPCR. A 41-fold overexpression of cdkn1a in the eye of six6b knockdown embryos 
was found (p-value = 0.001) (Figure 3), showing that in vivo downregulation of six6b affects the 
expression levels not only of cdkn2a/cdkn2b but also of cdkn1a, likely by binding to their sequence, 
repressing their expression. 
Figure 3. cdkn1a mRNA expression change 
Overexpression of cdkn1a and cdkn2a/cdkn2b  in response to six6b depletion is shown. All samples 
expression were normalized to the control gene sdha. Relative expression was calculated by setting 
the wild-type expression level at 1. Values represent mean ± standard error of the mean. *P<0.05; 
**P<0.005. 
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Discussion 
This meta-analysis within the IGGC identified a novel genomic region associated with IOP, nine 
genomic regions associated with VCDR, five with cup area, and six with disc area. Eleven genomic 
regions were associated with POAG. Of these regions, the association between CDKN1A and POAG is 
novel.  
We identify some specific loci that underlie the genetic correlation between IOP and VCDR described 
earlier[12]. ADAMTS8 and ABO were genome-wide significant for both IOP and VCDR or cup area. 
Variants found close to ABO (rs8176672 for cup area and rs8176741 for IOP) are in LD (r2 >0.85) with 
rs12216891, which lies in an enhancer and promoter histone mark, suggesting a potential regulatory 
mechanism in that region. Furthermore, TRIOBP is genome-wide significant for cup area, and reached 
a p-value of 3.42 x 10-6 for IOP. Interestingly, TRIOBP is approximately 180 kb away from CARD10 
which is associated with disc area.  There is a large overlap between VCDR/cup area and disc area. 
Since VCDR is related to disc area, it might be that the effect found for VCDR is due to the effect of 
disc area. Most of these overlapping genes are still Bonferroni significant in the cup area analysis in 
which we corrected for disc area. Only CDC7/TGFBR3 and F5 are genome-wide significant for VCDR as 
well as for disc area, but the effect is negligible after correction for disc area, suggesting that these 
two genes play primarily a role in disc area. 
When suggestive SNPs (p-value <1.0 x 10-5) for VCDR and cup area are analyzed together using 
DEPICT, we found an enrichment of pathways involved in cell differentiation, development, 
regulatory DNA binding and Notch signaling. Including disc area SNPs to the VCDR and cup area 
analysis reveals additional joint pathways: 1) eye and blood vessel development, 2) cancer, 3) protein 
import into nucleus, and 4) thrombospondin 1 and SMAD3 complexes, related to the extracellular 
matrix. Of interest,  known POAG genes also fit in these pathways identified in this paper based on 
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endophenotypes: GAS7 and SIX6 play a role during development[20, 22], TGFBR3 has been 
implicated in extracellular matrix regulation[23] and in cancer as well as GMDS[24].  
The extracellular matrix pathway has been previously implicated in optic nerve degeneration[14], 
and emerges in the DEPICT analyses. Both ADAMTS8 and COL8A1 have a role in this pathway. The 
encoded protein of the novel identified gene VCAN (versican) is also a major component of the 
extracellular matrix. Another member of the ADAMTS family (ADAMTS5) plays a role in the 
regulation of versican[25]. Interestingly, mutations in VCAN have been implicated in several 
ophthalmologic disorders[26]. 
The gene CDKN2B encodes a cyclin-dependent kinase inhibitor. Its antisense (CDKN2B-AS1) was one 
of the first POAG genes identified by GWAS. The gene CDKN1A, also known as p21, CIP-1 or WAF-1, is 
a gene from the same family as CDKN2B and also encodes a cyclin-dependent kinase inhibitor. 
Upregulation of CDKN1A causes G1 arrest and inhibits proliferation of the cell. Herein, for the first 
time, we provide genome-wide significant evidence for association of CDKN1A variants with cup 
area. Two prior small cohort studies suggested a possible role of CDKN1A in POAG. Tsai et al.[27] 
found an association between a codon 31 polymorphism in CDKN1A and POAG in 58 patients and 59 
controls from China (OR = 2.39 [1.14-5.01]). Saglar et al. found no statistically significant association 
between the codon 31 polymorphism and POAG in 75 patients and 119 controls from Turkey (OR = 
1.70, p-value = 0.25)[28]. Our study provides strong evidence for the role of CDKN1A in POAG risk in a 
large sample consisting of 6,429 cases and 41,404 controls and shows the first convincing evidence 
for association of CDKN1A and POAG in individuals of European descent. In addition, our in vivo 
studies in embryonic zebrafish eye showed that knockdown of six6b upregulates both 
cdkn2a/cdkn2b and cdkn1a. In a recent study, Skowronska-Krawczyk et al. showed that SIX6 
regulates the expression of CDKN2A, located in the same locus of CDKN2B and CDKN2B-AS1. The 
authors proposed that IOP elevation leads to CDKN2A upregulation through increased expression of 
SIX6. Increased CDKN2A causes senescence of retinal ganglion cells[29]. In our study, we found that 
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depletion, instead of upregulation of six6b leads to increased levels of cdkn2a/cdkn2b. Dual 
transcription activities of the SIX proteins have been described before. During development, for 
example, depending on the developmental context, SIX proteins can activate or repress their target 
genes[30]. Interestingly, the outcome of either SIX6 as transcriptional repressor or activator seems to 
be the upregulation of the CDK inhibitor genes (CDKN1A, CDKN2A and CDKN2B). More 
comprehensive studies at the individual tissue level e.g. retinal ganglion cell layer or optic nerve 
should be performed to evaluate the molecular mechanisms behind the upregulation of the CDK 
inhibitor genes in the context of normal and high tension glaucoma. 
The synthesis of CDKN1A is increased by the binding of p53 to p53-specific DNA consensus 
sequence[31, 32]. It has been suggested that p53 plays a role in POAG, especially in POAG with 
paracentral visual field loss[33].In a p53 knockout mouse model, less apoptosis was observed after 
induction of high IOP. Suggesting that the downregulation of p53 could attenuate the cell damage 
caused by high IOP levels[29]. Other genes also play a role in p53. GADD45A is involved in growth 
arrest through p53 dependent and independent mechanisms[31, 34] and can interact via 
CDKN1A[35]. Other novel identified genes might also play a role in p53-induced apoptosis. It has 
been shown that the secreted pdzd2 protein activates p53 by transcriptional regulation[36]. Also 
RREB1 has an effect on p53 by binding to its promotor and transactivates its expression[37]. This 
gene encodes a zinc finger transcription factor. This can bind to the RAS-responsive element of the 
calcitonin gene promotor which subsequently increases the expression of calcitonin. Calcitonin may 
be involved in the Ras/Raf signaling cascade that plays a role in the morphogenesis of retinal ganglion 
cells, the cell type affected by glaucoma, during neurogenesis[38]. Also PSCA is probably involved in 
p53-related pathways[39]. Other genes play a role in apoptosis or cell growth via other pathways 
than p53: VGLL4 inhibits Bax- and TNFa-induced apoptosis[40] and DGKB is a regulator of 
diacylglycerol, which is important for cell growth and differentiation. UGT8 plays a role in the 
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biosynthesis of the sphingolipids of myelin membranes of the central and peripheral nervous system; 
sphingolipids are also implicated in apoptosis[41]. 
Another interesting novel gene is RPE65 (retinal pigment epithelium -specific protein 65kDa). This 
gene has been associated with retinitis pigmentosa [42, 43] and Leber congenital amaurosis type 2 
(LCA2)[44]. As the name implies, the encoded protein is located in the retinal pigment 
epithelium[45]. It is involved in the conversion of all-trans retinal to 11-cis retinal, which is a 
necessary step in the visual cycle. Both diseases (RP and LCA2) are not characterized by an excavation 
of the optic nerve head. However, we have checked several online databases for expression in 
different tissues. In the eye, it is also highly expressed in the optic nerve head (S8 and S9 Tables) 
suggesting that this gene could be involved in other ocular processes . Little expression is found in 
the brain, with no expression in other tissues or organs in the body. Future studies are necessary to 
confirm our finding. 
Of the genes identified by gene-based testing, C9 (complement component 9) is especially  
interesting. Its protein is part of the membrane attack complex (MAC), together with the proteins 
C5b, C6, C7, and C8. This complex activates several steps that lead to cell death, and cells protect 
themselves by removing the complex through endocytosis. Caveolin is one of the proteins involved in 
endocytosis and the CAV1/CAV2 genes are associated with IOP and POAG. It has been shown that 
inhibition of caveolin-1 inhibits the endocytosis of MAC[46]. 
To our best knowledge, this meta-analysis is the largest study of IOP and optic nerve head 
parameters to date, using well-characterized datasets from populations world-wide. A limitation of 
our study is the lack of an available dataset for replication of the novel associations detected by 
combined European and Asian ancestry samples. However, the heterogeneity of these novel genomic 
regions is generally low in the meta-analysis. For VCDR, cup area, and disc area we have identified 
novel SNPs in the analysis of individuals with European ancestry. Of the nine novel associations found 
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in these populations (RPE65, PDZD2, RREB1, DGKB for VCDR; CDC42BPA, CRISPLD1 and FAM169B for 
cup area; and CTNNA3 and UGT8 for disc area), only RREB1 was nominally significant in the 
individuals with Asian ancestry. Five of the seven non-significant SNPs in the individuals with Asian 
ancestry had an effect estimate in the same direction. As the analysis in individuals with Asian 
ancestry contains a smaller number of individuals, this could be due to lack of power.  
We have identified 21 genetic variants associated with POAG endophenotypes. These association 
results do not imply that the variants described here have a causal effect. Fine-mapping and 
functional studies are required to identify the causal variants tagged by our findings and the exact 
molecular mechanisms involved in POAG. In conclusion, we have found novel genomic regions 
associated with the POAG endophenotypes: IOP, VCDR, cup area, and disc area. Although the overlap 
between IOP-loci and the optic disc parameters-loci is not large , this is the first study showing a 
genome-wide significant evidence of the genetic correlation between IOP and VCDR; we expect that 
larger sample sizes and improved imputation accuracy may help to find more of the loci underlying 
the genetic correlation between these two endophenotypes. Of the novel associations, CDKN1A is 
strongly associated with POAG, This finding is in line with other studies[29], pointing to the CDK-
inhibitor genes as key players in the development of POAG. The p53 pathway has been implicated in 
POAG, intriguingly, p53 has been also related to the CDK-inhibitors and to four of the new genes 
pointed out by this study (GADD45A, PDZD2, RREB1 and PSCA). Functional studies need to be 
performed to assess the role of p53 and CDK-inhibitors in the pathophysiology of POAG. A more 
comprehensive study of these mechanisms may inform the development of new therapies for POAG. 
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Methods 
Study design 
We performed a meta-analysis on directly genotyped and imputed SNPs to the 1000 Genomes 
reference panel. We analyzed four outcomes: IOP, VCDR, cup area, and disc area. In the first stage, 
we included 22,489-29,578 individuals with European ancestry. Subsequently, we evaluated the 
genome-wide significant SNPs from the first stage in 7,307-8,373 individuals with Asian ancestry. 
Finally, we performed a meta-analysis of GWAS summary findings from all individual studies 
including individuals with European and Asian ancestry. We subsequently tested the effect of all 
genome-wide significant SNPs on POAG in four independent case-control studies. 
 
Subjects, phenotyping and genotyping 
All 19 studies included in this meta-analysis are part of the IGGC (S1a Table).Details for each 
individual study can be found in S1b, S1c, and S2 Tables and the Supporting Information. The 
ophthalmological examinations included measurements of IOP and optic nerve head assessment. All 
19 studies contributed to the IOP mega/meta-analysis, 18 to the VCDR and 16 to the cup area and 
disc area mega/meta-analysis .Studies performed genomic imputation using 1000 Genomes phase 1 
reference samples . Study-specific quality control can be found in the Supporting Information. All 
studies were performed with the approval of their local medical ethics committee, and written 
informed consent was obtained from all participants in accordance with the Declaration of Helsinki. 
 
Statistical analysis 
In the IOP analysis, individuals who underwent IOP-lowering laser or surgery were removed from the 
analysis; in individuals receiving IOP-lowering medication, the IOP value was multiplied by 1.3 to 
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estimate a pre-medication IOP value[47]. The mean IOP, VCDR, cup area, and disc area of both eyes 
was used for the analyses. SNPs with MAF < 0.01 and imputation quality scores <0.3 (proper-info of 
IMPUTE) or R2<0.3 (MACH) were removed from the analyses. Each individual study performed a 
linear regression between each endophenotype (IOP, VCDR, cup area, and disc area) and the SNPs, 
under the assumption of an additive model for the effect of the risk allele. Analyses were adjusted 
for age, sex and the first five principal components (for population-based studies) or family structure 
(for family-based studies). 
We performed an inverse variance weighted fixed-effect meta-analysis with METAL software[48]. P 
values for heterogeneity were calculated by using the Cochran’s Q-test for heterogeneity. SNPs with 
a p-value for heterogeneity <0.001 were removed from the results, as well as SNPs only present in 
three studies. We used the ‘genomic control’ option in METAL to correct the standard error of each 
individual study for estimated genomic inflation. In the meta-analyses of individuals with European 
ancestry, a p-value <5.0 x 10-8 (the genome-wide threshold of association) was considered significant. 
In the second stage, these genome-wide significant SNPs were validated in individuals with Asian 
ancestry, and in this look-up a p value <0.05 was considered significant. Finally, in the meta-analysis 
of individuals with European and Asian ancestry a p-value of <5.0 x 10-8 was considered significant. In 
total, we identified 75 independent SNPs across different genomic regions for all the traits together. 
Therefore, the significance level after Bonferroni correction  in the meta-analysis of POAG cohorts  
was = 6.67 x 10-4 (0.05 / 75 independent SNPs). To estimate the common effect size of the top SNPs 
associated with IOP, optic disc parameters and their effect in the look-up in the POAG cohorts a 
random-effect meta-analysis was performed using plink[49] 
http://pngu.mgh.harvard.edu/purcell/plink/ parameter --meta-analysis. Manhattan, regional and 
forest plots were made using R[50] and LocusZoom[51]. 
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Gene-based test using VEGAS 
A gene-based test was performed using the VEGAS2 software[52], with a 50kb gene boundary. We 
used the parameter ‘-top 100’ (default) to perform gene-based tests. This parameter considers 
association test statistics of all variants mapped to a gene to compute gene-based test statistics. The 
1000 Genomes European and Asian populations were used as a reference to calculate LD for 
European and Asian ancestry data respectively. After calculation of gene-based test statistics for 
Asian and European ancestry populations separately, meta-analyses were conducted using Fisher’s 
method for combining p-values. 
 
Functional characterization, expression data, zebrafish and gene-set enrichment 
We investigated for evidence of regulatory functions of associated loci HaploReg version 2[53] and 
Regulomedb version 1.1[54]. We investigated the expression of the associated genes using NCBI’s 
UniGene[17] and The Ocular Tissue Database[18]. We also investigated the expression of cdkn1a in a 
six6b knockdown zebrafish and used DEPICT to investigate gene-set enrichment. More information 
about these analyses can be found in the Supporting Information. 
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